CN1527713A - 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法 - Google Patents

使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法 Download PDF

Info

Publication number
CN1527713A
CN1527713A CNA028126726A CN02812672A CN1527713A CN 1527713 A CN1527713 A CN 1527713A CN A028126726 A CNA028126726 A CN A028126726A CN 02812672 A CN02812672 A CN 02812672A CN 1527713 A CN1527713 A CN 1527713A
Authority
CN
China
Prior art keywords
glucocorticoid receptor
delirium
receptor antagonists
administration
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028126726A
Other languages
English (en)
Chinese (zh)
Inventor
Լɪ��K������ŵ��
约瑟夫K·贝拉诺夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of CN1527713A publication Critical patent/CN1527713A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CNA028126726A 2001-05-04 2002-05-06 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法 Pending CN1527713A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28861901P 2001-05-04 2001-05-04
US60/288,619 2001-05-04
US13780002A 2002-05-01 2002-05-01
US10/137,800 2002-05-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN 200510130359 Division CN1853638A (zh) 2001-05-04 2002-05-06 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法

Publications (1)

Publication Number Publication Date
CN1527713A true CN1527713A (zh) 2004-09-08

Family

ID=26835589

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028126726A Pending CN1527713A (zh) 2001-05-04 2002-05-06 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法

Country Status (11)

Country Link
EP (1) EP1390037B1 (https=)
JP (2) JP2005512949A (https=)
CN (1) CN1527713A (https=)
AT (1) ATE492281T1 (https=)
AU (1) AU2002303652B2 (https=)
CA (1) CA2446506C (https=)
DE (1) DE60238671D1 (https=)
IL (2) IL158744A0 (https=)
NO (1) NO334736B1 (https=)
NZ (1) NZ529456A (https=)
WO (1) WO2002096433A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116168840A (zh) * 2023-04-23 2023-05-26 北京大学人民医院 一种预测术后谵妄发生风险的方法、设备及系统

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60230936D1 (de) * 2001-10-26 2009-03-05 Organon Nv Verwendung von (11beta, 17beta)-11-(1,3-Benzodioxol-5-yl)-17-Hydroxy-17-(1-Propinyl)-estra-4,9-dien-3-on zur Behandlung von schweren Depressionen
JP6053802B2 (ja) * 2011-10-07 2016-12-27 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 患者を監視し、患者のせん妄を検出する監視システム

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3464012B2 (ja) * 1993-04-05 2003-11-05 旭化成株式会社 精神症候治療剤
IL110309A0 (en) * 1993-07-15 1994-10-21 Univ Kentucky Res Found A method of protecting against neuron loss
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction
IL139672A (en) * 1998-05-15 2005-11-20 Univ Leland Stanford Junior Glucocorticoid receptor antagonists for the tretment of dementia
DE60232956D1 (de) * 2001-03-23 2009-08-27 Corcept Therapeutics Inc Verfahren zur behandlung von stressbedingten erkrankungen unter verwendung von glucocorticoid-rezepto-spezifischen antagonisten

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116168840A (zh) * 2023-04-23 2023-05-26 北京大学人民医院 一种预测术后谵妄发生风险的方法、设备及系统
CN116168840B (zh) * 2023-04-23 2023-12-22 北京大学人民医院 一种预测术后谵妄发生风险的方法、设备及系统

Also Published As

Publication number Publication date
EP1390037A1 (en) 2004-02-25
EP1390037A4 (en) 2005-03-30
NO20034916L (no) 2004-01-05
JP2009102346A (ja) 2009-05-14
AU2002303652B2 (en) 2006-08-31
HK1059036A1 (en) 2004-06-18
CA2446506C (en) 2012-04-10
WO2002096433A9 (en) 2003-02-06
IL158744A (en) 2011-11-30
JP2005512949A (ja) 2005-05-12
ATE492281T1 (de) 2011-01-15
WO2002096433A1 (en) 2002-12-05
IL158744A0 (en) 2004-05-12
NO334736B1 (no) 2014-05-19
NO20034916D0 (no) 2003-11-04
NZ529456A (en) 2005-10-28
CA2446506A1 (en) 2002-12-05
EP1390037B1 (en) 2010-12-22
DE60238671D1 (de) 2011-02-03

Similar Documents

Publication Publication Date Title
CN1556709A (zh) 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
CN1130200C (zh) 用于治疗痴呆的糖皮质激素受体拮抗剂
CN1547473A (zh) 预防由抗精神病药物引起的体重增加的方法
AU2002255845A1 (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
US6620802B1 (en) Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
CN1556708A (zh) 抑制成年唐氏综合症患者认知退化的方法
US7884091B2 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
CN1527713A (zh) 使用糖皮质激素受体特效拮抗剂治疗谵妄症的方法
AU2002303652A1 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
AU2006233254B8 (en) Methods for treating delirium using glucocorticoid receptor-specific antagonists
ES2356729T3 (es) Uso de antogonistas específicos del receptor de glucocorticoides para el tratamiento del delirio.
HK1059036B (en) Use of glucocorticoid receptor-specific antagonists for the treatment of delirium
HK1098342A (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
HK1068283A (en) Methods for treating stress disorders using glucocorticoid receptor-specific antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication